About: Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence
Creator	Guilhaumou, Romain Montastruc, Jean-Louis Molimard, Mathieu Laporte, Silvy Roustit, Matthieu Drici, Milou
Source	Elsevier; Medline; PMC
abstract	Summary Chloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any efficacy of this drug in patients with COVID-19, due to major methodological weaknesses. Yet, these preliminary studies have aroused considerable media interest, raising fears of massive and uncontrolled use. In the absence of evidence of clinical benefits, the main risk is of exposing patients unnecessarily to the well-known adverse effects of hydroxychloroquine, with a possibly increased risk in the specific setting of COVID-19. In addition, widespread use outside of any recommendation risks compromising the completion of good quality clinical trials. The chloroquine hype, fueled by low-quality studies and media announcements, has yielded to the implementation of more than 150 studies worldwide. This represents a waste of resources and a loss of opportunity for other drugs to be properly evaluated. In the context of emergency, rigorous trials are more than ever needed in order to have, as soon as possible, reliable data on drugs that are possibly effective against the disease. Meanwhile, serious adverse drug reactions have been reported in patients with COVID-19 receiving hydroxychloroquine, justifying to limit its prescription, and to perform suitable cardiac and therapeutic drug monitoring.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.therap.2020.05.010
bibo:pmid	32473812
has license	els-covid
sha1sum (hex)	69e1b549b40d2dd1e67b5f138ed143f5618aedec
schema:url	https://doi.org/10.1016/j.therap.2020.05.010
resource representing a document's title	Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence
has PubMed Central identifier	PMC7244425
has PubMed identifier	32473812
schema:publication	Therapie
resource representing a document's body	covid:69e1b549b40d2dd1e67b5f138ed143f5618aedec#body_text
is schema:about of	named entity 'adverse drug reactions' named entity 'effective' named entity 'addition' named entity 'patients' named entity 'management' named entity 'HYDROXYCHLOROQUINE' named entity 'ADDITION' named entity 'DUE TO' named entity 'COVID-19' named entity 'PROPOSED' named entity 'raising' named entity 'hydroxychloroquine' named entity 'waste' named entity 'cardiac' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'COVID' named entity 'therapeutic drug monitoring' named entity 'COVID' named entity 'Chloroquine' named entity 'hydroxychloroquine' named entity 'epidemic' named entity 'SARS-Cov-2' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'Chloroquine' named entity 'completion' named entity 'hydroxychloroquine' named entity 'PCR' named entity 'viral load' named entity 'TDM' named entity 'randomized, controlled trial' named entity 'open-label' named entity 'France' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'hydroxychloroquine' named entity 'therapeutic drug monitoring' named entity 'viral infections' named entity 'hydroxychloroquine' named entity 'hepatitis C virus' named entity 'virus' named entity 'arthralgia' named entity 'false positive' named entity 'ADRs' named entity 'potassium current' named entity 'resuscitation' named entity 'adverse drug reactions' named entity 'cytochrome P450' named entity 'hydroxychloroquine' named entity 'peer-reviewed' named entity 'oxygen' named entity 'hydroxylated' named entity 'ADRs' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'EC50' named entity 'COVID' named entity 'randomization' named entity 'glycosylation' named entity 'infection' named entity 'HIV positive' named entity 'hypokalemia' named entity 'azithromycin' named entity 'arrhythmias' named entity 'hydroxychloroquine' named entity 'standard treatment' named entity 'ECG' named entity 'cinchonism' named entity 'ADRs' named entity 'viruses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software